Warning letter
Oregon Compounding Centers, Inc. dba Creative Compounds: warning letter of Jan 27, 2015
FDA warning letter 444376 · Seattle District Office
Key facts
| Reference number | 444376 |
|---|---|
| Company | Oregon Compounding Centers, Inc. dba Creative Compounds |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Jan 27, 2015 |
| Posted date | Feb 10, 2015 |
| Issuing office | Seattle District Office |
| Product type | Drugs |
| CFR sections cited | 211.42(c)(10)(iv), 211.113(b), 211.166(a), 211.42(c)(10)(v), 201.115, 211, 211.192, 211.28(a) |
| Inspection city | Wilsonville |
| Inspection ZIP | 97070 |
| Inspection start date | Aug 4, 2014 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: